Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, researchers have found that the combination of docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective alone or as a backbone regimen for newly developed targeted agents for the treatment of patients with advanced gastric cancer.
For this phase 2 study, researchers sought to evaluate docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/capecitabine (TEX), and TEF in patients with metastatic or locally recurrent gastric adenocarcinoma. Researchers randomly assigned 248 patients with advanced gastric cancer 1:1:1 to TE, TEF, or TEX.
Results showed a median progression survival of 7.66 months (95% CI: 6.97 - 9.40) for TEF, 4.50 months (95% CI: 3.68 - 5.32) for TE, and 5.55 months (95% CI: 4.30 - 6.37) for TEX. Median overall survival was 14.59 months (95% CI: 11.70 - 21.78) for TEF, 8.97 months (95% CI: 7.79 - 10.87) for TE, and 11.30 months (95% CI: 8.08 - 14.03) for TEX.
Tumor response rate for TEF was nearly double that of TE and TEX. Adverse effects were similar across all arms. The researchers suggest that TEF should be studied in phase 3 trials for patients with advanced gastric cancer alone or with targeted therapy.
Docetaxel, oxaliplatin, and TEF may be effective for the treatment of patients with advanced gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Chemotherapy Plays a Role in Skeletal Muscle Atrophy in Patients With Breast Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models
- Plastics and Cancer
- Real World Experience Differs from Trial Results for Niraparib in Recurrent Ovarian Cancer
- Trastuzumab Biosimilar Demonstrated Equivalent Efficacy Across Clinical Settings
- Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers